Answers are grounded in this paper and cite their sources.
Drug resistance often enters lead optimization after a compound has been chosen. We define distributed robustness as redistributing predicted binding support away from predefined mutable contacts while retaining wild-type feasibility and panel coverage. ResistAgent separates site-level and observed combination-level liabilities, diagnoses their structural effects, and compares a matched-budget robust objective with an average-affinity comparator. Across 10 EGFR pairs, the median reduction in hotspot dependence, ΔDep (naive − robust; positive values favor the robust objective), was +0.042; across 9 valid HIV-RT pairs, it was +0.026. Panel passing was preserved but not improved: both objectives passed in every valid pair. ABL1 yielded 2/4 pairs without a corresponding robustness gain. The objective changes the dependence organization and candidate selection. Provider comparisons, ranking benchmarks, and explicit-water contact descriptors are reported alongside the primary endpoint.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: